tiprankstipranks
Amplia Therapeutics Announces Director’s Share Acquisition
Company Announcements

Amplia Therapeutics Announces Director’s Share Acquisition

Amplia Therapeutics Ltd. (AU:ATX) has released an update.

Stay Ahead of the Market:

Amplia Therapeutics Ltd., an Australian pharmaceutical company specializing in Focal Adhesion Kinase inhibitors for cancer and fibrosis, has announced a change in the director’s interest. Dr. Christopher Burns has acquired 347,826 ordinary shares and 260,869 listed options in the company. This move highlights ongoing developments in Amplia’s strategic focus on targeting fibrotic cancers and chronic diseases.

For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles